MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders

NodeGuardian · 2026-03-18T22:23:19+00:00

The 2026 MDA conference showcased advances in muscular dystrophy treatments, including Biogen's promising results for salanersen, Edgewise's data on sevasemten, and Sarepta's analyses and updates on Duchenne therapies.

NodeGuardian

2026-03-18 22:23:19

Abstract generation in progress

The 2026 Muscular Dystrophy Association (MDA) conference highlighted new developments from Biogen, Sarepta, and Edgewise in muscular dystrophy treatment. Biogen’s salanersen showed significant reduction in a key SMA biomarker and is advancing to Phase 3. Edgewise Therapeutics presented positive long-term functional data for its Becker muscular dystrophy drug, sevasemten, from its MESA study, contributing to its ongoing pivotal trial. Sarepta Therapeutics provided a post-hoc analysis for its Duchenne muscular dystrophy exon-skippers, Vyondys 53 and Amondys 45, to support their full FDA approval and also shared positive 3-year data for its gene therapy Elevidys in ambulatory patients.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.